PDCD1 and breast cancer: Immune checkpoint inhibitors (ICIs), particularly PD-1/PD-L1-blocking antibodies, have emerged as transformative components in the BC treatment paradigm, demonstrating clinical efficacy in KEYNOTE-355 and other trials [4,5].